Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background: Lopinavir/ritonavir-containing antiretro-viral therapy can cause hyperlipidaemia. However, most statins are contraindicated due to drug-drug interactions. Rosuvastatin undergoes minimal metabolism by CYP 450 , so no CYP 450 -based interaction with lopinavir/ritonavir is expected. This study explored the lipid-lowering effect of rosuvastatin and assessed the effect of lopinavir/ritonavir on the pharmacokinetics of rosuvastatin and vice versa. Methods: HIV-infected patients on lopinavir/ritonavir (viral load <400 copies/ml) with total cholesterol (TC) >6.2 mmol/l were treated with rosuvastatin for 12 weeks, starting on 10 mg once daily. If fasting target values (TC<5.0 mmol/l, high-density lipoprotein-cholesterol >1.0 mmol/l, low-density lipoprotein-cholesterol [LDL-c] <2.6 mmol/l and triglycerides <2.0 mmol/l) were not reached, rosuvastatin was escalated to 20 mg or 40 mg at week 4 and 8, respectively. Plasma lopinavir/ritonavir trough levels (C min ) were determined at week 0, 4, 8 and 12 and rosuvastatin C min , at week 4, 8 and 12. Results: Twenty-two patients completed the study. Mean reductions in TC and LDL-c from baseline to week 4 (on rosuvastatin 10 mg once a day) were 27.6% and 31.8%, respectively. Lopinavir/ritonavir concentrations were not influenced by rosuvastatin ( P=0.44 and 0.26, repeated-measures analysis). Median (interquartile range) rosuvastatin C min for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70–1.5), 2.5 (1.3–3.3) and 5.5 (3.3–8.8) ng/ml, respectively. Conclusions: Rosuvastatin appeared to be an effective statin in hyperlipidaemic HIV-infected patients. Lopinavir/ritonavir levels were not affected by rosuvastatin, but rosuvastatin levels unexpectedly appeared to be increased 1.6-fold compared with data from healthy volunteers. Until safety and efficacy have been confirmed in larger studies, the combination of rosuvastatin and lopinavir/ritonavir should be used with caution.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the combination of rosuvastatin with lopinavir/ritonavir should also be used with caution.215”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [215]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
König, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.1.g156 · Cited by 620
Dubé, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D., Glesby, M. J., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/378131 · Cited by 580
Lopinavir/Ritonavir: A Review of its Use in the Management of HIV Infection
Cvetkovic, R. S., & Goa, K. L. (2003) · Drugs · doi:10.2165/00003495-200363080-00004 · Cited by 436
46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Vila, J., & Bonomo, R. A. (2007) · Future Microbiology · doi:10.2217/17460913.2.1.9 · Cited by 420
McTaggart, F., Buckett, L., Davidson, R., Holdgate, G., McCormick, A., Schneck, D., Smith, G., & Warwick, M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01454-0 · Cited by 413
Schambelan, M., Benson, C. A., Carr, A., Currier, J. S., Dubé, M. P., Gerber, J. G., Grinspoon, S. K., Grunfeld, C., Kotler, D. P., Mulligan, K., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200211010-00001 · Cited by 379
Early statin therapy restores endothelial function in children with familial hypercholesterolemia
de Jongh, S., Lilien, M. R., op’t Roodt, J., Stroes, E. S. G., Bakker, H. D., & Kastelein, J. J. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02593-7 · Cited by 367
Self-citationFichtenbaum, C. J., Gerber, J. G., Rosenkranz, S. L., Segal, Y., Aberg, J. A., Blaschke, T., Alston, B., Fang, F., Kosel, B., & Aweeka, F. (2002) · AIDS · doi:10.1097/00002030-200203080-00008 · Cited by 338
SIMONSON, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.010 · Cited by 330
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009290 · Cited by 302
Metabolism, Excretion, and Pharmacokinetics of Rosuvastatin in Healthy Adult Male Volunteers
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80336-3 · Cited by 286 · cited 1×
“important role in the clearance of rosuvastatin [5,6]; rosuvastatin is only minimally metabolized by CYP3A4 [7].”
BackgroundMartin, P. D., Mitchell, P. D., & Schneck, D. W. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01688.x · Cited by 148
Hsyu, P.-H., Schultz-Smith, M. D., Lillibridge, J. H., Lewis, R. H., & Kerr, B. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3445-3450.2001 · Cited by 143
Droste, J. A. H., Wissen, C. P. W. G. M. V.-V., & Burger, D. M. (2003) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200306000-00023 · Cited by 133
Self-citationStatins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART
Calza, L., Manfredi, R., & Chiodo, F. (2003) · AIDS · doi:10.1097/00002030-200304110-00010 · Cited by 121
Effect of itraconazole on the pharmacokinetics of rosuvastatin
Cooper, K. D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(02)17633-8 · Cited by 115
The effect of fluconazole on the pharmacokinetics of rosuvastatin
Cooper, K., Martin, P. D., Dane, A. L., Warwick, M. J., Schneck, D. W., & Cantarini, M. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0508-8 · Cited by 113
Hull, C. K., Penman, A. D., Smith, C., & Martín, P. (2002) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00088-0 · Cited by 104
Martin, P. D., Dane, A. L., Schneck, D. W., & Warwick, M. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80089-9 · Cited by 103
Corbett, A., Lim, M. L., & Kashuba, A. D. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a363 · Cited by 100
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects
Cooper, K. J., Martin, P. D., Dane, A. L., Warwick, M. J., Raza, A., & Schneck, D. W. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01720.x · Cited by 97
The effect of erythromycin on the pharmacokinetics of rosuvastatin
Cooper, K. J., Martin, P. D., Dane, A. L., Warwick, M. J., Raza, A., & Schneck, D. W. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0573-7 · Cited by 87
Calza, L., Manfredi, R., & Chiodo, F. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00115-8 · Cited by 83
Rosuvastatin in the management of hyperlipidemia
Cheng, J. W. M. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.09.005 · Cited by 78
Carswell, C., Plosker, G. L., & Jarvis, B. (2002) · Drugs · doi:10.2165/00003495-200262140-00008 · Cited by 78
Calza, L., Colangeli, V., Manfredi, R., Legnani, G., Tampellini, L., Pocaterra, D., & Chiodo, F. (2005) · AIDS · doi:10.1097/01.aids.0000174458.86121.43 · Cited by 77
Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C
Brown, C., Windass, A. S., Bleasby, K., & Lauffart, B. (2001) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(01)80225-7 · Cited by 60
Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics
Simonson, S. G., Martin, P. D., Mitchell, P., Lasseter, K. C., Gibson, G. L., & Schneck, D. W. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005278224 · Cited by 52
29th Annual Meeting American College of Clinical Pharmacology September 17–19, 2000 Chicago
(2000) · The Journal of Clinical Pharmacology · doi:10.1177/jcph.2000.40.9.1045 · Cited by 8
Research works printed but not linked: 3
- Crestor, 2006, SmPC Crestor. The Medicines Evaluation Board the Netherlands.
- Norvir, Summary of Product Characteristics.
- Hoody D., Kiser J., Predhomme J., Flynn D., Gerber J. Drug-drug interaction between lopinavir/ritonavir and rosuvastatin. 14th Conference on Retroviruses and Opportunistic Infections , 25–28 February 2007, Los Angeles, CA, USA. Abstract 564.
Cited by
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
Barton, H. A., Lai, Y., Goosen, T. C., Jones, H. M., El-Kattan, A. F., Gosset, J. R., Lin, J., & Varma, M. V. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759210 · Cited by 68
Metadata
- Authors
- Van Der Lee, M., Sankatsing, R., Schippers, E., Vogel, M., Fätkenheuer, G., Van Der Ven, A., Kroon, F., Rockstroh, J., Wyen, C., Bäumer, A., De Groot, E., Koopmans, P., Stroes, E., Reiss, P., & Burger, D.
- Affiliations
- Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
- Amsterdam UMC Location University of Amsterdam (NL)
- Leiden University Medical Center (NL)
- University of Bonn (DE)
- University of Cologne (DE)
- Nijmegen University Centre for Infectious Diseases, Nijmegen, the Netherlands
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
- Radboud University Nijmegen (NL)
- ORCID
- Venue
- Antiviral Therapy
- Publisher
- SAGE Publications
- Published
- 2007-10
- Volume
- 12
- Issue
- 7
- Pages
- 1127-1132
- ISSN
- 1359-6535 (ISSN-L)
- 2040-2058
- OpenAlex
- W1480085725
- Cited by
- 78
- References
- 33
- Citations by year
- 2022: 2 · 2021: 5 · 2020: 8 · 2019: 1 · 2018: 1 · 2016: 5 · 2015: 3 · 2014: 3 · 2013: 6 · 2012: 5
- FWCI
- 9.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Antiviral Therapy (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Keywords
- lopinavir/ritonavir, rosuvastatin, drug-drug interactions, HIV infection, hyperlipidemia, hypolipidemic effect, pharmacokinetics, pharmacodynamics, antiretroviral therapy, statins, cytochrome P450 metabolism, LDL cholesterol, total cholesterol, trough concentration, dose escalation, lipid-lowering therapy
- MeSH terms
- Rosuvastatin Calcium, Adolescent, Adult, Aged, Drug Therapy, Combination, Fluorobenzenes, Humans, Hypercholesterolemia, Middle Aged, Pilot Projects, Pyrimidines, Pyrimidinones, Sulfonamides, HIV Infections, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Anti-HIV Agents, Ritonavir, Lopinavir
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.